ES2827277T3 - Anticuerpo anti-c-Met - Google Patents

Anticuerpo anti-c-Met Download PDF

Info

Publication number
ES2827277T3
ES2827277T3 ES18188726T ES18188726T ES2827277T3 ES 2827277 T3 ES2827277 T3 ES 2827277T3 ES 18188726 T ES18188726 T ES 18188726T ES 18188726 T ES18188726 T ES 18188726T ES 2827277 T3 ES2827277 T3 ES 2827277T3
Authority
ES
Spain
Prior art keywords
antibody
amino acid
met
cdr
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18188726T
Other languages
English (en)
Spanish (es)
Inventor
Liliane Goetsch
Thierry Wurch
Cédric Bes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2827277(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Application granted granted Critical
Publication of ES2827277T3 publication Critical patent/ES2827277T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)
  • Medicinal Preparation (AREA)
ES18188726T 2008-12-02 2009-12-02 Anticuerpo anti-c-Met Active ES2827277T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
US18450209P 2009-06-05 2009-06-05

Publications (1)

Publication Number Publication Date
ES2827277T3 true ES2827277T3 (es) 2021-05-20

Family

ID=41693124

Family Applications (3)

Application Number Title Priority Date Filing Date
ES18188726T Active ES2827277T3 (es) 2008-12-02 2009-12-02 Anticuerpo anti-c-Met
ES16192250T Active ES2697098T3 (es) 2008-12-02 2009-12-02 Anticuerpo anti-c-Met
ES09771324.2T Active ES2629855T3 (es) 2008-12-02 2009-12-02 Nuevo anticuerpo anti-c-Met

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES16192250T Active ES2697098T3 (es) 2008-12-02 2009-12-02 Anticuerpo anti-c-Met
ES09771324.2T Active ES2629855T3 (es) 2008-12-02 2009-12-02 Nuevo anticuerpo anti-c-Met

Country Status (38)

Country Link
US (4) US8741290B2 (enExample)
EP (4) EP3757132A1 (enExample)
JP (3) JP5863458B2 (enExample)
KR (1) KR101838299B1 (enExample)
CN (2) CN103351438B (enExample)
AR (1) AR074439A1 (enExample)
AU (3) AU2009328318C1 (enExample)
BR (2) BRPI0923231B8 (enExample)
CA (1) CA2743433C (enExample)
CL (2) CL2011001296A1 (enExample)
CO (1) CO6382139A2 (enExample)
CR (1) CR20110324A (enExample)
CY (2) CY1119172T1 (enExample)
DK (2) DK3135691T3 (enExample)
EC (1) ECSP11011127A (enExample)
ES (3) ES2827277T3 (enExample)
GE (2) GEP20135930B (enExample)
HR (2) HRP20171011T8 (enExample)
HU (3) HUE051288T2 (enExample)
IL (2) IL213273A0 (enExample)
LT (2) LT2370468T (enExample)
MA (1) MA32892B1 (enExample)
MX (2) MX2011005677A (enExample)
MY (2) MY185200A (enExample)
NZ (1) NZ593853A (enExample)
PE (1) PE20120343A1 (enExample)
PH (1) PH12015501515A1 (enExample)
PL (3) PL3135691T3 (enExample)
PT (3) PT3431502T (enExample)
RS (2) RS56204B1 (enExample)
RU (2) RU2015127471A (enExample)
SA (2) SA109300720B1 (enExample)
SG (2) SG187518A1 (enExample)
SI (3) SI2370468T1 (enExample)
TN (1) TN2011000216A1 (enExample)
TW (2) TWI459964B (enExample)
WO (1) WO2010069765A1 (enExample)
ZA (1) ZA201105164B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
KR20140019284A (ko) 2010-09-03 2014-02-14 아카데미아 시니카 항-C-Met 항체 및 이의 이용 방법들
EP3165538A1 (en) 2010-11-03 2017-05-10 Argen-X Nv Anti c-met antibodies
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
KR101463098B1 (ko) 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
US10377827B2 (en) 2012-06-21 2019-08-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9994644B2 (en) 2013-04-30 2018-06-12 Agency For Science, Technology And Research mAB 2 anti-Met antibody
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
RU2656153C1 (ru) * 2013-12-20 2018-05-31 Девелопмент Сентер Фор Байотекнолоджи Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
WO2016149265A1 (en) * 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof
US10927177B2 (en) 2016-02-05 2021-02-23 Helixmith Co., Ltd Methods of treatment using anti-c-met antibodies
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
RS60663B1 (sr) 2016-05-17 2020-09-30 Abbvie Biotherapeutics Inc Konjugati anti-cmet antitelo-lek i metodi za njihovu primenu
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20180230218A1 (en) * 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh) 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
JP7482363B2 (ja) * 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020198731A2 (en) * 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
AU2022253888A1 (en) 2021-04-06 2023-09-28 AbbVie Manufacturing Management Unlimited Company Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
MX2023011929A (es) * 2021-04-08 2023-10-23 Byondis Bv Anticuerpos anti-c-met y conjugados de anticuerpo-farmaco.
UY39743A (es) * 2021-04-29 2022-11-30 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023173109A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin and osimertinib
AU2024276234A1 (en) 2023-05-23 2025-12-04 AbbVie Manufacturing Management Unlimited Company Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) * 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
RU2292904C2 (ru) * 2001-01-09 2007-02-10 Мерк Патент Гмбх Комбинированная терапия, использующая ингибиторы рецептора тирозинкиназы и ингибиторы ангиогенезиса
MXPA05008521A (es) * 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1922208A (zh) * 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
RU2398777C2 (ru) * 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
CA2854576A1 (en) * 2005-07-18 2007-01-25 Haichun Huang Human anti-b7rp1 neutralizing antibodies
WO2007016285A2 (en) 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
MX2008012485A (es) * 2006-03-30 2008-10-10 Novartis Ag Composiciones y metodos de uso para anticuerpos de c-met.
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
RU2015127471A (ru) 2018-12-21
BRPI0923231B8 (pt) 2021-05-25
SA112331005B1 (ar) 2015-09-13
US20130109841A1 (en) 2013-05-02
WO2010069765A1 (en) 2010-06-24
AR074439A1 (es) 2011-01-19
CA2743433A1 (en) 2010-06-24
TWI459964B (zh) 2014-11-11
ES2629855T3 (es) 2017-08-16
SA109300720B1 (ar) 2013-05-25
US20110239316A1 (en) 2011-09-29
MY185200A (en) 2021-04-30
US8729249B2 (en) 2014-05-20
MA32892B1 (fr) 2011-12-01
PT3135691T (pt) 2018-11-27
CN102227446B (zh) 2015-10-21
GEP20135930B (en) 2013-10-10
JP2017099392A (ja) 2017-06-08
TW201446805A (zh) 2014-12-16
EP3135691B1 (en) 2018-08-15
PE20120343A1 (es) 2012-04-16
US8741290B2 (en) 2014-06-03
JP2016117721A (ja) 2016-06-30
IL231525A0 (en) 2014-04-30
US8747850B2 (en) 2014-06-10
MX2011005677A (es) 2011-06-30
ES2697098T3 (es) 2019-01-22
MY192567A (en) 2022-08-29
EP3431502A1 (en) 2019-01-23
AU2009328318A1 (en) 2011-07-28
CN103351438A (zh) 2013-10-16
AU2016200725C1 (en) 2017-10-19
US8765128B2 (en) 2014-07-01
HRP20181868T1 (hr) 2019-01-11
RU2560257C2 (ru) 2015-08-20
RU2011124751A (ru) 2013-01-10
JP6309657B2 (ja) 2018-04-11
SG187518A1 (en) 2013-02-28
BRPI0923231B1 (pt) 2020-04-28
EP2370468A1 (en) 2011-10-05
HUE051288T2 (hu) 2021-03-01
AU2016200725A1 (en) 2016-02-25
LT2370468T (lt) 2017-07-10
CN102227446A (zh) 2011-10-26
CY1119172T1 (el) 2018-02-14
DK3135691T3 (en) 2018-11-19
DK2370468T3 (en) 2017-06-19
BRPI0923231A2 (pt) 2016-01-26
MX341014B (es) 2016-08-03
TWI523866B (zh) 2016-03-01
GEP20146207B (en) 2014-12-10
CO6382139A2 (es) 2012-02-15
CL2011001296A1 (es) 2011-08-26
RS58018B1 (sr) 2019-02-28
EP3135691A1 (en) 2017-03-01
TW201023892A (en) 2010-07-01
NZ593853A (en) 2013-03-28
HUE035047T2 (en) 2018-05-02
AU2017203929A1 (en) 2017-07-06
HRP20171011T1 (hr) 2017-09-22
CY1121025T1 (el) 2019-12-11
IL231525B (en) 2019-07-31
JP6074018B2 (ja) 2017-02-01
PL3431502T3 (pl) 2020-12-28
AU2016200725B2 (en) 2017-05-25
RS56204B1 (sr) 2017-11-30
PT2370468T (pt) 2017-07-13
LT3135691T (lt) 2018-11-12
SG171851A1 (en) 2011-07-28
BR122019023930B1 (pt) 2021-05-04
SI3431502T1 (sl) 2021-01-29
EP3431502B1 (en) 2020-07-22
EP2370468B1 (en) 2017-04-05
ZA201105164B (en) 2012-03-28
US20130109844A1 (en) 2013-05-02
US20130109840A1 (en) 2013-05-02
PL3135691T3 (pl) 2019-02-28
ECSP11011127A (es) 2011-07-29
CA2743433C (en) 2019-06-11
CR20110324A (es) 2011-07-28
CL2014000181A1 (es) 2014-07-25
PT3431502T (pt) 2020-10-29
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
KR101838299B1 (ko) 2018-03-14
JP2012510280A (ja) 2012-05-10
JP5863458B2 (ja) 2016-02-16
AU2009328318B2 (en) 2015-11-05
CN103351438B (zh) 2016-04-20
EP3757132A1 (en) 2020-12-30
HK1190414A1 (zh) 2014-07-04
HK1162536A1 (zh) 2012-08-31
KR20110097839A (ko) 2011-08-31
AU2017203929B2 (en) 2019-03-28
TN2011000216A1 (en) 2012-12-17
PL2370468T3 (pl) 2017-09-29
SI3135691T1 (sl) 2018-12-31
HUE040553T2 (hu) 2019-03-28
AU2009328318C1 (en) 2017-11-02
SI2370468T1 (sl) 2017-08-31
PH12015501515A1 (en) 2015-12-14

Similar Documents

Publication Publication Date Title
ES2827277T3 (es) Anticuerpo anti-c-Met
CA2801264C (en) Novel anti-cmet antibody
US20230406940A1 (en) ANTI-cMET ANTIBODY
WO2010064089A1 (en) Novel anti-cmet antibody
US20130216527A1 (en) Novel anti-cmet antibody